Regulatory expectations for medicinal products in the context of COVID-19

The European Commission (EC), European Medicines Agency (EMA) and the European medicines regulatory network have developed a question-and-answer (Q&A) document for stakeholders on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients. Read more “Regulatory expectations for medicinal products in the context of COVID-19”